Treatment Strategy for Ultra-High-Risk Multiple Myelomas with Chromosomal Aberrations Considering Minimal Residual Disease Status and Bone Marrow Microenvironment

SIMPLE SUMMARY: Proteasome inhibitors, immunomodulatory drugs, anti-CD38 monoclonal antibodies (triple class drugs), and autologous stem cell transplantation (ASCT) are promising myeloma treatments that have resulted in minimal residual disease (MRD) negativity and improvement in the bone marrow mic...

Descripción completa

Detalles Bibliográficos
Autores principales: Suzuki, Kazuhito, Yano, Shingo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177433/
https://www.ncbi.nlm.nih.gov/pubmed/37173885
http://dx.doi.org/10.3390/cancers15092418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10177433/
https://www.ncbi.nlm.nih.gov/pubmed/37173885
http://dx.doi.org/10.3390/cancers15092418

Ejemplares similares